Claims for Patent: 7,119,093

Summary for Patent: 7,119,093

Title:	3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-an- ilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulpho- nate and the use thereof as a pharmaceutical composition
Abstract:	The present invention relates to the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycabonyl-2-indolinone-monoethanesulpho- nate of formula I and the use thereof as a pharmaceutical composition ##STR00001##
Inventor(s):	Roth; Gerald J. (Biberach, DE), Linz; Guenter (Mittelbiberach, DE), Sieger; Peter (Mittelbiberach, DE), Rall; Werner (Mittelbiberach, DE), Hilberg; Frank (Wien, AT), Bock; Thomas (Biberach, DE)
Assignee:	Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, DE)
Application Number:	10/623,971
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,119,093
Patent Claims:	1. 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino- )-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesu- lphonate. 2. 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino- )-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesu- lphonate hemihydrate in crystalline form, having a melting point of T.sub.m.p.=305.+-.5.degree. C. (determined by DSC; evaluation using peak-maximum; heating rate: 10.degree. C./min). 3. Crystalline 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulph- onate hemihydrate according to claim 2, the X-ray powder diagram of which includes, inter alia, the characteristic values d=5.43 .ANG., 5.08 .ANG., 4.71 .ANG., 4.50 .ANG. and 4.43 .ANG. with an intensity of more than 40%. 4. Crystalline 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulph- onate hemihydrate according to claim 2, characterised by a unit cell determined by X-ray powder diffractometric measurements having the following dimensions: a=16.332 .ANG., b=19.199 .ANG., c=11.503 .ANG., .alpha.=95.27.degree., .beta.=90.13.degree., .gamma.=110.83.degree. and V=3354.4 .ANG..sup.3. 5. A pharmaceutical composition comprising 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulph- onate and one or more inert carriers and/or diluents. 6. A prodrug of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulph- onate. 7. 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino- )-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesu- lphonate hemihydrate in crystalline form.